Prior to prescribing, administering, dispensing, ordering, selling, supplying, or giving a Schedule III or IV amphetamine-like controlled substance to treat obesity in a patient sixteen (16) years of age or older, the physician shall obtain and review:
a. JNC Obesity Guidelines
b. CDCP Report
c. KASPER Report
d. DNPAO Guidelines
Answer:(c). Kentucky All Schedule Prescription Drug Electronic Reporting System (KASPER) report, [201 KAR 9:016 Section 4].
(1). Prior to prescribing, administering, dispensing, ordering, selling, supplying, or giving a Schedule III or IV amphetamine-like controlled substance to treat obesity in a patient sixteen (16) years of age or older, the physician shall:
(a). Establish a physician/patient relationship;
(b). Determine that the patient is obese or overweight with medical risk factors and is a proper candidate for weight reduction treatment;
(c). Determine and record the extent of prior anorectics or other controlled substances used by the patient.
The prescribing physician shall obtain and review a KASPER report for the twelve (12) month period immediately preceding the patient encounter, before prescribing or dispensing controlled substances to the patient.
(2). During treatment for obesity, a physician shall:
(a). Maintain a physician/patient relationship throughout the treatment process;
(b). Maintain an adequate patient record in accordance with subsection (4) of this section; and
(c). Justify in the patient record the use of any Schedule III or IV amphetamine-like controlled substance beyond three (3) months.
Before the physician continues the use of a substance beyond three (3) months, the physician shall obtain and review a current KASPER report.